SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by…

UroGen Pharma Ltd. · PRESS-RELEASE filed May 6, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 6, 2026 at 08:00 ET

UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +109% QoQ) and JELMYTO growth ($21.7M, +7% YoY). Net loss narrowed to $23.6M ($0.47/share) from $43.8M ($0.92/share) a year ago, beating the consensus EPS estimate of -$0.48. The company maintained JELMYTO revenue guidance of $97-101M and operating expense guidance of $240-250M for 2026.

  • Total revenue $51.0M vs $20.3M YoY (+152%), beating consensus $44.8M
  • ZUSDURI net product revenue $29.2M in first full quarter of launch (109% QoQ growth)
  • JELMYTO revenue $21.7M (+7% YoY), in line with full-year guidance of $97-101M
  • Net loss $23.6M ($0.47/share) vs consensus -$0.48, a beat

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access